What is the official website of Novartis Magyarország ?

The official website of Novartis Magyarország is https://www.novartis.hu.

What is Novartis Magyarország's cybersecurity risk score?

Novartis Magyarország has an AI-generated cybersecurity risk score of 751 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Magyarország experienced?

According to Rankiteo, Novartis Magyarország currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Magyarország been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Magyarország has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Magyarország have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Magyarország is not certified under SOC 2 Type 1.

Does Novartis Magyarország have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Magyarország does not hold a SOC 2 Type 2 certification.

Does Novartis Magyarország comply with GDPR ?

According to Rankiteo, Novartis Magyarország is not listed as GDPR compliant.

Does Novartis Magyarország have PCI DSS certification ?

According to Rankiteo, Novartis Magyarország does not currently maintain PCI DSS compliance.

Does Novartis Magyarország comply with HIPAA ?

According to Rankiteo, Novartis Magyarország is not compliant with HIPAA regulations.

Does Novartis Magyarország have ISO 27001 certification ?

According to Rankiteo,Novartis Magyarország is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Magyarország operate in ?

Novartis Magyarország operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Magyarország have ?

Novartis Magyarország employs approximately 44 people worldwide.

Does Novartis Magyarország own any subsidiaries ?

Novartis Magyarország presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Magyarország have ?

Novartis Magyarország's official LinkedIn profile has approximately 2,570 followers.

What is the NAICS classification code for Novartis Magyarország ?

Novartis Magyarország is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Magyarország have a Crunchbase profile ?

No, Novartis Magyarország does not have a profile on Crunchbase.

Does Novartis Magyarország have a LinkedIn profile ?

Yes, Novartis Magyarország maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-magyarorszag.

How many cybersecurity incidents has Novartis Magyarország experienced ?

As of September 10, 2026, Rankiteo reports that Novartis Magyarország has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Magyarország have ?

Novartis Magyarország has an estimated 5,760 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Magyarország faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Magyarország

Boost Score +25 with badge (5 left)

751

/1000

Fair

776

/1000

Fair

Novartis Magyarország Vendor Cyber Rating & Cyber Score

novartis.hu

Add Your Compliance Badge

A Novartisnál újragondoljuk az orvoslást azért, hogy jobbá tegyük és meghosszabbítsuk az emberek életét. Világszinten vezető egészségügyi vállalatként a tudományos alapokon nyugvó innovációt ötvözzük a digitális technológiai megoldásokkal azért, hogy olyan terápiákat hozzunk létre, amelyek választ adnak a társadalmi szempontból legnagyobb kihívást jelentő egészségügyi problémákra. Azon küldetésünk során, hogy új gyógymódokat fedezzünk fel, folyamatosan a kutatás-fejlesztésre legtöbbet fordító világcégek élvonalában helyezkedünk el. A Novartis Csoport a legnagyobb árbevételű gyógyszercég Magyarországon. A vállalat innovatív gyógyszerek forgalmazásával, valamint Sandoz divízióján keresztül generikus és biohasonló termékek forgalmazásával

Novartis Magyarország

Novartis Magyarország CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Magyarorsz...

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Magyarország Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Magyarország

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Magyarország in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Magyarország in 2026.

Incident Types Novartis Magyarország vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Magyarország in 2026.

Incident History - Novartis Magyarország (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Magyarország Subsidiaries

Novartis Magyarország

Pharmaceutical Manufacturing

Website: https://www.novartis.hu

Company Size: 44

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis EspañaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Loading…

Novartis Magyarország Similar Companies

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Loading…

NEWS

Novartis Magyarország CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-87924

SUMMARY

A security vulnerability has been detected in Rizwan17 inventory-management-system up to bfe78a330d01bb26b9daec5dc9ecd5c77900e03f. This affects an unknown part of the file includes/invoice_bill.php of the component Invoice Generation. Such manipulation of the argument order_date/invoice_no leads to missing authentication. It is possible to launch the attack remotely. The exploit has been disclosed publicly and may be used. This product takes the approach of rolling releases to provide continious delivery. Therefore, version details for affected and updated releases are not available. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: 6.5)

cvss2

Base Score: 6.4

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:P

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-87923

SUMMARY

A weakness has been identified in Rizwan17 inventory-management-system up to bfe78a330d01bb26b9daec5dc9ecd5c77900e03f. Affected by this issue is some unknown functionality of the file includes/DBOperation.php of the component List Handler. This manipulation of the argument category_name/brand_name/product_name causes cross site scripting. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. This product is using a rolling release to provide continious delivery. Therefore, no version details for affected nor updated releases are available. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-71809

SUMMARY

Authentication Bypass via Hardcoded Master Verification Code vulnerability in Siam Ordering (siam-server) 1.0.0 allows remote unauthenticated attackers to log in as any user, merchant, or administrator.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/W000i/vuln/issues/11

CVE-2026-15460

SUMMARY

The Bluetooth Classic (BR/EDR) L2CAP receive handler bt_l2cap_br_recv() in subsys/bluetooth/host/classic/l2cap_br.c dispatched inbound data PDUs based only on the destination channel ID, without checking that the target channel had reached the BT_L2CAP_CONNECTED state. A dynamic channel is assigned its RX CID and added to the connection's channel list while still in BT_L2CAP_CONNECTING (and later BT_L2CAP_CONFIG) — before configuration completes and, for PSMs that require security, before the peer is authenticated (l2cap_br_conn_req()). Because the channel is already findable by bt_l2cap_br_lookup_rx_cid() during this window, a remote peer within radio range can send a data PDU addressed to that CID and have it processed on a not-yet-established channel. The dispatch keys off channel fields (BR_CHAN(chan)->rx.mode, rx.mps) that are only initialized during configuration by l2cap_br_conf(); since channel objects are pooled and bt_l2cap_br_chan_del() does not reset rx.mode or the reassembly buffer _sdu, a reused channel can carry stale state into the CONNECTING window and route the frame into the retransmission/flow-control path (bt_l2cap_br_ret_fc_recv()) with stale parameters and a possibly stale _sdu pointer. The impact is delivery of attacker data to upper-layer protocol handlers on a half-open (and possibly unauthenticated) channel, plus operation on stale or partially initialized channel state on reused channel objects — leading to channel/link teardown (denial of service) and, in the stale-_sdu case, a dangling-pointer condition. The fix adds an explicit BR_CHAN(chan)->state < BT_L2CAP_CONNECTED guard that drops any data received before the channel is fully connected.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

Impact Score

2.5

Exploitability

2.8

REFERENCES

CVE-2026-88069

SUMMARY

Pandora contains a path traversal vulnerability in its archive extraction worker. When processing a specially crafted archive or disk image, attacker-controlled file paths could be used without ensuring that the resulting destination remained within the intended extraction directory. An attacker able to submit a malicious file for analysis could use path traversal sequences or crafted paths to cause extracted content to be written outside the designated extraction directory, potentially overwriting files accessible to the Pandora worker process. Successful exploitation could result in unauthorized modification of application or system files, denial of service, and potentially further compromise depending on the permissions of the Pandora process and the files that can be overwritten. The vulnerability is addressed by resolving each extraction destination path before writing and verifying that it remains below the expected extraction directory. Extraction attempts resolving outside this directory are rejected and reported as path traversal attempts.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:H/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/pandora-analysis/pandora/commit/d86ac5b260fb9a41e07f1da1bbd326cdcfc188a7

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Magyarország Vendor Cyber Rating & Cyber Score

Novartis Magyarország A.I CyberSecurity Scoring

Novartis Magyarország CyberSecurity News & History

Novartis Magyarország Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Magyarország

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Magyarország vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Magyarország (X = Date, Y = Severity)

Novartis Magyarország Subsidiaries

Novartis Magyarország

Novartis Magyarország Similar Companies

UCB

MACLEODS PHARMACEUTICALS LTD.

MSD

Intas Pharmaceuticals

Teva Pharmaceuticals

Bristol Myers Squibb

Merck

Hikma Pharmaceuticals

Lupin

Novartis Magyarország CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Magyarország CyberSecurity News & History

Novartis Magyarország Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Magyarország

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Magyarország vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Magyarország (X = Date, Y = Severity)

Novartis Magyarország Subsidiaries

Novartis Magyarország

Novartis Magyarország Similar Companies

UCB

MACLEODS PHARMACEUTICALS LTD.

MSD

Intas Pharmaceuticals

Teva Pharmaceuticals

Bristol Myers Squibb

Merck

Hikma Pharmaceuticals

Lupin

Novartis Magyarország CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo